Research digest · GLP-1 receptor agonist
Semaglutide: what the GLP-1 receptor pharmacology and twenty years of clinical trials have actually measured
A mechanistic and clinical-evidence digest for the compound with the largest Phase 3 trial program in its drug class. Every quantitative claim drawn from the published literature — cited, attributed, and organized.
What the Semaglutide literature has established
Semaglutide is a 31-amino-acid synthetic analogue of human glucagon-like peptide-1 (GLP-1), engineered with structural modifications that extend plasma half-life from the native hormone's ~2 minutes to approximately 168 hours — enabling once-weekly subcutaneous dosing. The compound's evidence base is the largest of any GLP-1 receptor agonist, spanning six named trial series (SUSTAIN, PIONEER, STEP, SELECT, ESSENCE, OASIS) plus active Phase 3 work in metabolic-associated steatohepatitis, alcohol use disorder, and adolescent obesity.
The headline numbers are well-characterized. Subcutaneous semaglutide at 2.4 mg weekly produced a mean 14.9% body weight reduction versus 2.4% with placebo over 68 weeks in adults without type 2 diabetes — 86.4% of treated participants achieved at least 5% weight loss [1]. In cardiovascular outcome research, the SELECT trial enrolled 17,604 adults with obesity and established cardiovascular disease and found a 20% relative reduction in the composite risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.80, 95% CI 0.72–0.90) over a mean 39.8 months [2].
Semaglutide is FDA-approved for three distinct indications: type 2 diabetes management (subcutaneous, 2017; oral, 2019), chronic weight management in adults with obesity or overweight plus a weight-related condition (subcutaneous 2.4 mg, 2021), and — as of 2025 — metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. The adolescent weight management indication (≥12 years) was approved in 2022.
This site documents the pharmacological mechanism, the clinical trial record, and the pharmacokinetic profile. It does not sell, prescribe, or dispense semaglutide in any form.
What Is Semaglutide?
Semaglutide is a peptide drug — a 31-amino-acid GLP-1 receptor agonist that is an analogue of human glucagon-like peptide-1, sharing approximately 94% structural homology with the native hormone. Three deliberate structural modifications define the compound's pharmacokinetics.
First, the amino acid at position 8 is substituted with alpha-aminoisobutyric acid (Aib), which shields that residue from DPP-4 enzyme cleavage — the mechanism by which native GLP-1 is degraded in plasma within minutes. Second, lysine at position 34 is replaced with arginine to prevent GIP cross-reactivity. Third, a C18 fatty diacid chain is attached via a flexible linker to lysine at position 26, enabling reversible albumin binding in plasma. Albumin binding dramatically slows renal clearance and provides further steric protection against DPP-4 — the combined effect produces the ~168-hour terminal half-life [13].
The result is an oral-or-injectable peptide that acts at GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract with far greater potency and duration than native GLP-1. semaglutide GLP-1 receptor agonist pharmacology is detailed on the mechanism page.
Regulatory Status of Semaglutide
Semaglutide carries multiple FDA approval milestones across different formulations and indications.
Subcutaneous semaglutide was approved for type 2 diabetes management in December 2017, at doses of 0.5 mg and 1.0 mg once weekly. An oral formulation was approved in September 2019 at 7 mg and 14 mg daily for type 2 diabetes — the first oral GLP-1 receptor agonist to reach approval, enabled by co-formulation with the SNAC absorption enhancer. The 2.4 mg subcutaneous dose for chronic weight management in adults was approved in June 2021, followed by the adolescent indication (≥12 years) in 2022. An investigational 7.2 mg dose demonstrated greater weight loss in the STEP UP trial (2025) [17].
In August 2025, FDA approved the 2.4 mg subcutaneous formulation for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis — the first GLP-1 agonist approval for liver disease — following Phase 3 ESSENCE trial results showing 62.9% MASH resolution versus 34.3% placebo [8].
Semaglutide is not on the WADA Prohibited List as of 2024.
Semaglutide as a Peptide Compound
Semaglutide belongs to the peptide drug class — it is a chain of 31 amino acids, not a small molecule. This distinction has practical consequences: the compound cannot be absorbed orally without an absorption enhancer (SNAC, in the oral formulation), and it does not cross the blood-brain barrier efficiently via passive diffusion — its central nervous system effects on appetite are mediated via circumventricular organs and hypothalamic projections that lack a complete blood-brain barrier.
At a molecular weight of 4,113.6 Da, semaglutide is larger than most injectable pharmaceuticals but smaller than biologic antibodies. Its status as a peptide shapes its manufacturing (solid-phase peptide synthesis followed by fatty-acid conjugation), its storage requirements (refrigerated, solution-based pre-filled pens for subcutaneous use), and its degradation pathway (proteolytic cleavage, not hepatic CYP450 metabolism — explaining the clean drug-drug interaction profile) [15].
This site focuses on semaglutide's pharmacology as a peptide GLP-1 receptor agonist. See the semaglutide mechanism of action page for full receptor-binding and signaling pathway detail.
Semaglutide Research Indications
The published research covers five active indication areas, with the MASH and addiction findings representing 2024–2025 expansions of the compound's evidence base.
Type 2 diabetes: The SUSTAIN trial series (SUSTAIN-1 through SUSTAIN-10) established semaglutide's glycemic efficacy and cardiovascular safety in type 2 diabetes. SUSTAIN-6 demonstrated a 26% reduction in MACE in 3,297 high-cardiovascular-risk T2D patients (HR 0.74, 95% CI 0.58–0.95) [3].
Obesity and chronic weight management: The STEP trial series (STEP 1 through STEP 8, TEENS, UP) characterizes semaglutide's weight management profile, with consistent mean weight loss in the 14–19% range across studies. semaglutide for weight loss is covered in detail on the dedicated page.
Cardiovascular outcomes: SELECT enrolled 17,604 adults with obesity without diabetes; the primary MACE outcome reduction (20%, HR 0.80) established semaglutide as a cardiovascular risk-reducing agent independent of glycemic action [2].
MASH/MAFLD: ESSENCE (N=1,197, 2025) documented 62.9% MASH resolution versus 34.3% placebo — the first Phase 3 GLP-1 trial to show reversal of both steatohepatitis and liver fibrosis [8].
Addiction and CNS: A 2025 Phase 2 randomized controlled trial (N=48) demonstrated significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder [9], supported by preclinical mechanistic work showing modulation of GABA neurotransmission in the amygdala and infralimbic cortex [10].